7AC Stock Overview
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out in Sweden and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Acarix AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.02 |
52 Week High | kr0.055 |
52 Week Low | kr0.014 |
Beta | 1.42 |
1 Month Change | -8.68% |
3 Month Change | 29.03% |
1 Year Change | -36.31% |
3 Year Change | -81.57% |
5 Year Change | -94.46% |
Change since IPO | -99.12% |
Recent News & Updates
Recent updates
Shareholder Returns
7AC | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 17.6% | -0.6% | 1.6% |
1Y | -36.3% | 2.8% | 6.4% |
Return vs Industry: 7AC underperformed the German Medical Equipment industry which returned 2.8% over the past year.
Return vs Market: 7AC underperformed the German Market which returned 6.4% over the past year.
Price Volatility
7AC volatility | |
---|---|
7AC Average Weekly Movement | 36.4% |
Medical Equipment Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7AC's share price has been volatile over the past 3 months.
Volatility Over Time: 7AC's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 20 | Aamir Mahmood | https://www.acarix.com |
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out in Sweden and internationally. It offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced AI to analyze the patient's coronary blood flow. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Acarix AB (publ) Fundamentals Summary
7AC fundamental statistics | |
---|---|
Market cap | €16.08m |
Earnings (TTM) | -€6.79m |
Revenue (TTM) | €544.68k |
29.5x
P/S Ratio-2.4x
P/E RatioIs 7AC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7AC income statement (TTM) | |
---|---|
Revenue | kr6.24m |
Cost of Revenue | kr944.00k |
Gross Profit | kr5.30m |
Other Expenses | kr83.14m |
Earnings | -kr77.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
Earnings per share (EPS) | -0.11 |
Gross Margin | 84.87% |
Net Profit Margin | -1,247.22% |
Debt/Equity Ratio | 0% |
How did 7AC perform over the long term?
See historical performance and comparison